Buprenorphine Hydrochloride Tablet
Product Images NDC 70518-4571

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Buprenorphine Hydrochloride (NDC 70518-4571). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Buprenorphine 8mg 70518 4571 00)

This text provides details about buprenorphine sublingual tablets, including manufacturing information, dosage, storage instructions, and precautions related to children's access and legal regulations. It also mentions the quantity per box, expiration date, and a caution regarding the transfer of the drug to unauthorized individuals. Additionally, it indicates that the medication was repackaged by RemedyRepack, a company based in Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

This is information about Buprenorphine sublingual tablets manufactured by PAl Pharma in Greenville, SC. The tablets are 8 mg and are intended for oral use. The tablets should be stored at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). The packaging includes details such as NDC number, lot number, expiration date, and the caution to keep the medication out of reach of children. Additionally, the tablets are repackaged by Remedy Inc. in Indiana, PA.*

FDA Label Image

Chemical Structure (Buprenorphine Hydrochloride 1)

FDA Label Image

Figure (Buprenorphine Hydrochloride 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.